Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LS301-IT for Intraoperative Imaging of Lung Cancer
NCT06713564Phase 1Completed
- Sponsor
- Integro Theranostics
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of ls301 in lung cancer (4 cohorts), sponsored by Integro Theranostics. Primary endpoints: Number of Patients with Dose Limiting Toxicities and Number of Patients that discontinue the study or have their surgery cancelled due to toxicity. Started Nov 2024; status: completed.
02
Drugs
ls301
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06713564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713564.